ANS Pharmacology Autosaved

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 17

Autonomic Nervous System

(ANS) Pharmacology
Kitz Kyiel M. Espartero, RN, MAN
INTRODUCTION

• The central nervous system (CNS) is the body’s primary nervous system and
consists of the brain and spinal cord.
• The peripheral nervous system (PNS), located outside the brain and spinal cord,
is made up of two divisions: the autonomic and the somatic.
• The autonomic nervous system (ANS), also called the visceral system, acts on
smooth muscles and glands. Its functions include control and regulation of the
heart, respiratory system, gastrointestinal tract, bladder, eyes, and glands. The
ANS is an involuntary nervous system, over which we have little or no control:
we breathe, our hearts beat, and peristalsis continues without our realizing it.
• the somatic nervous system is a voluntary system that innervates skeletal
muscles, over which there is control.
The two sets of neurons in the autonomic component of the PNS are
the
1. afferent, or sensory, neurons
send impulses to the CNS, where they are interpreted.
2. efferent, or motor, neurons.
receive the impulses (information) from the brain and transmit these
impulses through the spinal cord to the effector organ cells.
• The efferent pathways in the ANS are divided into two branches: the
sympathetic and the parasympathetic nerves.
• these two branches are called the sympathetic nervous system and
the parasympathetic nervous system
The sympathetic nervous system is also called the adrenergic system
• neurotransmitter is norepinephrine.
• The adrenergic receptor organ cells are of four types: alpha1, alpha2, beta1,
and beta2
• Norepinephrine is released from the terminal nerve ending and stimulates
the cell receptors to produce a response.
The parasympathetic nervous system is called the cholinergic system
• neurotransmitter is acetylcholine.
• The cholinergic receptors at organ cells are either nicotinic or muscarinic,
meaning that they are stimulated by the alkaloids nicotine and muscarine,
respectively.
• Acetylcholine stimulates the receptor cells to produce a response, but the
enzyme acetylcholinesterase may inactivate acetylcholine before it reaches
the receptor cell.
Introduction to the Autonomic Nervous
System (ANS)
• Overview of ANS: Controls involuntary
functions like heart rate, BP, digestion, and
respiration.
• Divisions: Sympathetic (SNS) and
Parasympathetic (PNS)
• Neurotransmitters:
– Norepinephrine (SNS)
– Acetylcholine (PNS)
Pharmacology of the Sympathetic Nervous
System (SNS)
• Adrenergic Receptors:
– Alpha (α1, α2), Beta (β1, β2, β3)
• Alpha-1 (α1):
– Vasoconstriction, increased BP
• Beta-1 (β1):
– Increases heart rate and contractility
• Beta-2 (β2):
– Bronchodilation, vasodilation
Adrenergic Agonists (Sympathomimetics)

• Mechanism: Mimic norepinephrine or


epinephrine.
• Examples:
– Epinephrine (anaphylaxis),
– Albuterol (asthma),
– Dobutamine (heart failure)
Adrenergic Antagonists (Sympatholytics)

• Mechanism: Block effects of norepinephrine


and epinephrine.
• Examples:
– Propranolol (hypertension),
– Atenolol (angina),
– Prazosin (BPH)
Pharmacology of the Parasympathetic
Nervous System (PNS)
Cholinergic Receptors:
• Muscarinic receptors:
– Mediate rest-and-digest functions
• Nicotinic receptors:
– Involved in muscle contraction and transmission
Cholinergic Agonists
(Parasympathomimetics)
• Mechanism: Mimic acetylcholine.
• Examples:
– Bethanechol (urinary retention),
– Pilocarpine (glaucoma)
Anticholinergics (Parasympatholytics)
• Mechanism: Block acetylcholine at muscarinic
receptors.
• Examples:
– Atropine (bradycardia),
– Ipratropium (COPD),
– Scopolamine (motion sickness)
Adverse Effects and Nursing Considerations

• Adrenergic Drugs: Tachycardia, hypertension,


anxiety.
• Cholinergic Drugs: Bradycardia, hypotension,
increased secretions.
• Anticholinergics: Dry mouth, constipation,
urinary retention.
Clinical Application and Case Studies

1. A patient with asthma treated with a beta-2


agonist.
2. A hypertensive patient receiving a beta-blocker.
3. A patient with bradycardia treated with a
muscarinic antagonist.
4. Patient with Overactive Bladder Treated with a
Muscarinic Antagonist
References
• Lehne, R. A., Burchum, J. R., & Rosenthal, L. D.
(2019). Lehne’s Pharmacology for Nursing
Care (10th ed.). Elsevier.
• Lilley, L. L., Collins, S. R., & Snyder, J. S. (2020).
Pharmacology and the Nursing Process (10th
ed.). Elsevier.
• Ritter, J. M., Flower, R. J., Henderson, G., &
Rang, H. P. (2020). Rang & Dale's
Pharmacology (9th ed.). Elsevier.

You might also like